Due to the important role of the classical complement pathway in AChR-MG [4,5], and to unchanged plasma levels of the alternative pathway proteins Factor B and properdin [30], we suggest that the observed C2 and C5 consumption is mainly due to classical complement pathway activation in AChR-MG patients. This evidence concerns the gene C2 and myasthenia gravis.